Image: Patient Murray Rowland participates in first clinical trial of a suprachoroidal implant in Retinitis pigmentosa.
Original Published Date: 
Tuesday, September 30, 2014

Bionic Vision Australia (BVA)—a consortium of researchers working together to develop bionic eye devices to restore a sense of vision to people with profound vision loss—has announced the successful completion of the first clinical trial of its prototype 24-channel percutaneous implant in patients with profound vision loss from the eye disease retinitis pigmentosa (RP). RP is an inherited, degenerative eye disease that causes severe vision impairment and often blindness through progressive degeneration of the retina and death of the photoreceptors. The two-year Prototype 24-Channel Percutaneous Connector Study, which started in May 2012, involved three RP patients with profound vision loss (bare light perception only) who each received surgically implanted suprachoroidal electrode implants to aid the restoration of vision. Surgery was completed without any adverse events. BVA receives funding from the ARC as a Special Research Initiative for Research in Bionic Vision Science and Technology.

Media issued by Bionic Vision Australia